BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9169956)

  • 21. Prescribing of psychotropic drugs to children and adolescents.
    Adams S
    BMJ; 1991 Jan; 302(6770):217. PubMed ID: 1998763
    [No Abstract]   [Full Text] [Related]  

  • 22. Psychotropic drug versus psychotropic drug-update.
    Strain JJ; Chiu NM; Sultana K; Karim A; Caliendo G; Mustafa S; Strain JJ
    Gen Hosp Psychiatry; 2004; 26(2):87-105. PubMed ID: 15038926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of Youths Treated With Psychotropic Polypharmacy in the United States, 1999 to 2015.
    Zhang C; Spence O; Reeves G; dosReis S
    JAMA Pediatr; 2021 Feb; 175(2):196-198. PubMed ID: 33136150
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From the Editor-in-Chief's Desk.
    Koplewicz HS
    J Child Adolesc Psychopharmacol; 2018 Apr; 28(3):157. PubMed ID: 29641250
    [No Abstract]   [Full Text] [Related]  

  • 25. The 7 habits of highly effective psychopharmacologists, part 2: begin with the end in mind.
    Stahl SM
    J Clin Psychiatry; 2000 May; 61(5):327-8. PubMed ID: 10847305
    [No Abstract]   [Full Text] [Related]  

  • 26. Conflicting data on psychotropic use by children: two pieces to the same puzzle.
    Rubin D
    JAMA Pediatr; 2013 Feb; 167(2):189-90. PubMed ID: 23403948
    [No Abstract]   [Full Text] [Related]  

  • 27. Improving mental health treatments through comparative effectiveness research.
    Wang PS; Ulbricht CM; Schoenbaum M
    Health Aff (Millwood); 2009; 28(3):783-91. PubMed ID: 19414887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The adoption of mental health drugs on state AIDS drug assistance program formularies.
    Martin EG; Barry CL
    Am J Public Health; 2011 Jun; 101(6):1103-9. PubMed ID: 21493949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Reports. The psychopharmacological off-label prescribing in the treatment of children and adolescents with psychiatric disorders].
    Oehler KU; Romanos M; Uzelli-Schwarz O; Dieffenbach R; Vulturius G; Holtmann M; Wewetzer C
    Z Kinder Jugendpsychiatr Psychother; 2016; 44(4):315-7. PubMed ID: 27434690
    [No Abstract]   [Full Text] [Related]  

  • 30. [Generics in psychiatry--do they have the same therapeutic equivalence as the original?].
    Kasper S; Lentner S
    Neuropsychiatr; 2008; 22(4):221-2. PubMed ID: 19080992
    [No Abstract]   [Full Text] [Related]  

  • 31. Avoiding psychotropic drug interactions in the cardiovascular patient.
    DeVane CL; Markowitz JS
    Bull Menninger Clin; 2000; 64(1):49-59. PubMed ID: 10695159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychopharmacology: the need for effectiveness trials to inform evidence-based psychiatric practice.
    Lagomasino IT; Dwight-Johnson M; Simpson GM
    Psychiatr Serv; 2005 Jun; 56(6):649-51. PubMed ID: 15939939
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial: Off-label Treatments for Mental Health: Inappropriate or Unavoidable? A Special Issue to Help Get Through the Maze.
    Rolland B; Amad A
    Curr Pharm Des; 2015; 21(23):3274-5. PubMed ID: 26238988
    [No Abstract]   [Full Text] [Related]  

  • 34. [Bitter and gilded pills: psychiatry in the light (or shadow) of the pharmaceutical industry].
    Vandereycken W
    Tijdschr Psychiatr; 2006; 48(2):119-29. PubMed ID: 16958195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deep pharma: psychiatry, anthropology, and pharmaceutical detox.
    Oldani M
    Cult Med Psychiatry; 2014 Jun; 38(2):255-78. PubMed ID: 24700144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic versus brand name drugs in psychopharmacology: a pharmacoeconomic perspective.
    Emanuele E
    South Med J; 2011 Oct; 104(10):715-6. PubMed ID: 21941163
    [No Abstract]   [Full Text] [Related]  

  • 37. Psychotropic medication expenditures for community-dwelling elderly persons.
    Aparasu R; Mort J; Brandt H
    Psychiatr Serv; 2003 May; 54(5):739-42. PubMed ID: 12719508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of Medicare Part D prescription drug benefit: potential implications for patients with psychotic disorders.
    Rosenberg JM
    Am J Health Syst Pharm; 2007 Jan; 64(2 Suppl 1):S18-23; quiz S24-5. PubMed ID: 17215472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definition and management of suicidality in psychiatric patients.
    Fawcett JA; Baldessarini RJ; Coryell WH; Silverman MM; Stein DJ
    J Clin Psychiatry; 2009 Oct; 70(10):e38. PubMed ID: 19906337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in office-based practice under managed care.
    Kahan J
    Am J Psychiatry; 2000 Mar; 157(3):484-5. PubMed ID: 10698848
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.